首页 > 市场调查报告书 > 製药

非专利药糖尿病生物製剂生技仿製药

市场调查报告书

商品编码

1741457

基础胰岛素市场按类型、给药装置、适应症、年龄层、分销管道和地区划分

Basal Insulin Market, By Type, By Delivery Device, By Indication, By Age Group, By Distribution Channel, By Geography

出版日期: 2025年03月27日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

基础胰岛素市场规模预计在 2025 年为 196.5 亿美元，预计到 2032 年将达到 378.1 亿美元，2025 年至 2032 年的复合年增长率为 9.8%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	196.5亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	9.80%	2032年价值预测	378.1亿美元

基础胰岛素是一种长效胰岛素，可全天稳定释放胰岛素，以控製糖尿病患者的血糖值。它通常用于需要胰岛素治疗的第1型或第2型糖尿病患者。基础胰岛素有助于维持两餐之间和空腹期间的稳定血糖值，为最佳糖尿病管理奠定基础。

全球基础胰岛素市场正经历显着成长，这得益于全球糖尿病盛行率的不断上升。根据国际糖尿病联盟的数据，预计到2045年，全球成年糖尿病患者人数将达7亿人。糖尿病患者数量的成长刺激了对基础胰岛素的需求，而基础胰岛素是糖尿病管理的重要组成部分。

市场动态：

基础胰岛素市场受多种因素驱动。糖尿病（尤其是第2型糖尿病）盛行率的上升是市场的主要驱动力。久坐不动、不良饮食和肥胖等不健康的生活习惯导致全球糖尿病盛行率上升。因此，预计基础胰岛素的需求将大幅成长。

此外，胰岛素治疗技术的进步也推动了市场的成长。药物动力学特性得到改善的胰岛素类似物的开发显着提高了基础胰岛素治疗的疗效和便利性。这些进步带来了更好的血糖控制，并降低了低血糖风险。

例如，2023年10月23日，与中国製药公司通化东宝药业股份有限公司合作的临床阶段生物製药公司Adsia宣布，其Chaperone组合THDB0207（包含Insulin Lispro和Insulin Glargine）的三项临床试验取得了积极成果。这三项试验表明，BC组合是一种有效的胰岛素，兼具长效和速效胰岛素的特性。因此，它可以确保餐后和空腹血糖控制。

然而，基础胰岛素市场的成长仍面临许多阻碍因素。其中包括胰岛素治疗成本高、部分地区医疗保健服务有限等。此外，胰岛素生产和分销的严格监管要求也给市场参与者带来了挑战。

儘管面临这些挑战，基础胰岛素市场仍提供了许多成长机会。老年人口的成长以及人们对糖尿病管理重要性的认识不断提高，预计将推动市场成长。此外，智慧胰岛素输送系统的开发以及数位技术在糖尿病管理中的整合，也为市场参与者提供了新的探索途径。

本研究的主要特点

本报告对全球基础胰岛素市场进行了详细分析，包括预测期 2025-2032 的市场规模和年复合成长率(CAGR)，以 2024 年为基准年。
它揭示了不同领域的潜在收益成长机会，并解释了该市场的引人注目的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
根据公司亮点、产品系列、主要亮点、业绩和策略，列出了全球基础胰岛素市场的主要企业。
本报告的见解将使负责人和经营团队能够就未来的产品发布、产品类型升级、市场扩张和行销策略做出明智的决策。
全球基础胰岛素市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过用于分析全球基础胰岛素市场的各种策略矩阵来促进他们的决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 19.65 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	9.80%	2032 Value Projection:	USD 37.81 Bn

Basal insulin is a type of long-acting insulin that provides a steady release of insulin throughout the day and night to control blood sugar levels in individuals with diabetes. It is typically prescribed for individuals with type 1 diabetes or type 2 diabetes who require insulin therapy. Basal insulin helps maintain stable blood sugar levels between meals and during periods of fasting, providing a foundation for optimal diabetes management.

The global basal insulin market is experiencing significant growth, driven by the increasing prevalence of diabetes worldwide. According to the International Diabetes Federation, the number of adults with diabetes is expected to reach 700 million by 2045. This rise in diabetes cases is fueling the demand for basal insulin, as it is an essential component of diabetes management.

Market Dynamics:

The basal insulin market is driven by several factors. The rising prevalence of diabetes, particularly type 2 diabetes, is a key driver for the market. Unhealthy lifestyle habits, such as sedentary behavior, poor diet, and obesity, are contributing to the increasing incidence of diabetes globally. As a result, the demand for basal insulin is expected to rise significantly.

In addition, advancements in insulin therapy technologies are also driving the market growth. The development of insulin analogs, which have improved pharmacokinetic properties, has significantly enhanced the efficacy and convenience of basal insulin therapy. These advancements have led to better glycemic control and reduced risks of hypoglycemia.

For instance, on October 23, 2023, Adocia, a biopharmaceutical company in the clinical stage, announced that Tonghua Dongbao Pharmaceutical Co. Ltd., a pharmaceutical company based in China, is its partner and has released positive results from three clinical studies conducted on the BioChaperone Combo THDB0207 formulation, which contains insulin lispro and insulin glargine. These three studies showed that BC Combo is a useful insulin that combines the qualities of both long-acting and rapid-acting insulin. As a result, it can guarantee glycemic control during the postprandial and fasting periods.

However, there are certain restraints that may hinder the growth of the basal insulin market. The high cost of insulin therapy and limited access to healthcare in certain regions are some of the barriers. Additionally, the stringent regulatory requirements for insulin production and distribution pose challenges for market players.

Despite these challenges, there are several opportunities for growth in the basal insulin market. The increasing geriatric population, as well as the growing awareness about the importance of diabetes management, are expected to drive the market growth. Furthermore, the development of smart insulin delivery systems and the integration of digital technologies in diabetes management present new avenues for market players to explore.

Key Features of the Study:

This report provides an in-depth analysis of the global basal insulin market including market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, with 2024 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
Key players in the global basal insulin market are profiled based on company highlights, product portfolio, key highlights, financial performance, and strategies
Key companies covered in this study include Novo Nordisk, Sanofi, Eli Lilly and Company, Biocon, Gan & Lee Pharmaceuticals, Tonghua Dongbao Pharmaceutical, United Laboratories, Merck, Wockhardt, Julphar Diabetes, Medtronic, Beta Bionics, Zealand Pharma, MannKind, Peptron, Dexcom, Senseonics, Medtrum Technologies, SOOIL Development, and Semma Therapeutics
Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
The global basal insulin market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global basal insulin market

Basal Insulin Market Segmentation:

By Type
- Glargine
- Detemir
- Degludec
By Delivery Device
- Syringes
- Pens
- Pumps
- Others (Inhalers, Patches)
By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
By Age Group
- Pediatric
- Adults
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Biocon
- Gan & Lee Pharmaceuticals
- Tonghua Dongbao Pharmaceutical
- United Laboratories
- Merck
- Wockhardt
- Julphar Diabetes
- Medtronic
- Beta Bionics
- Zealand Pharma
- MannKind
- Peptron
- Dexcom
- Senseonics
- Medtrum Technologies
- SOOIL Development
- Semma Therapeutics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Basal Insulin Market, By Type
- Global Basal Insulin Market, By Delivery Device
- Global Basal Insulin Market, By Indication
- Global Basal Insulin Market, By Age Group
- Global Basal Insulin Market, By Distribution Channel
- Global Basal Insulin Market, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising prevalence of diabetes, particularly type 2 diabetes
- Restraints
High cost of insulin therapy
- Opportunities
Increasing geriatric population
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Basal Insulin Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Basal Insulin Market, By Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Glargine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Detemir
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Degludec
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Basal Insulin Market, By Delivery Device, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Syringes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Pens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Pumps
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others (Inhalers, Patches)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Basal Insulin Market, By Indication, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Type 1 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Type 2 Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Gestational Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

8. Global Basal Insulin Market, By Age Group, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

9. Global Basal Insulin Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

10. Global Basal Insulin Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Delivery Device, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

11. Competitive Landscape

Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Biocon
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Gan & Lee Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Tonghua Dongbao Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
United Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Wockhardt
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Julphar Diabetes
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Medtronic
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Beta Bionics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Zealand Pharma
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
MannKind
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Peptron
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Dexcom
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Senseonics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Medtrum Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
SOOIL Development
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Semma Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views

12. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

基础胰岛素市场按类型、给药装置、适应症、年龄层、分销管道和地区划分